Hepatology

Results from the retrospective cohort study indicated viral eradication with DAAs after liver transplantation improved liver function and patient survival after a long-term follow-up, even in cirrhotic patients.

Investigators highlighted an association between treatment retention over time and the out-of-pocket cost for patients with hepatic encephalopathy taking rifaximin.

Hypertension prevalence was significantly higher among adults with obesity and severe NAFLD, providing important information related to the association between hypertension and NAFLD severity.

A systematic review shows the muscle relaxant therapy is the lone intervention to benefit outcomes for the liver diseases among patients with alcohol use disorder, per randomized trials.

Investigators identified a strong magnitude of association between MAFLD and risk of CKD based on the results of a comprehensive meta-analysis.

A new study revealed differences in the diagnostic performance of the FIB-4 and NFS, indicating that conventional NFS cutoff values may be unsuitable for screening lean NAFLD patients.

Investigators find that while general hospitalizations decreased in 2020, hospitalizations due to alcohol-associated hepatitis increased by 16%.

New 12-week data shows an investigative oral drug provided significant benefit in key outcomes associated with NASH disease relief.

An analysis of postmenopausal women shows a nearly two-fold increase in liver cancer incidence among those who consume at least 1 soft drink or fruit drink daily.

Approximately 1 in 5 newly diagnosed patients are initiating direct acting antivirals within 6 months, according to Medicaid data review.

Experts in hepatology review the unmet needs in primary biliary cholangitis, commenting on liver transplant, ethnic disparities, management of pruritis, as well as other symptoms.

Sonal Kumar, MD, MPH, and David Victor III, MD, provide an overview of the emerging treatments in the primary biliary cholangitis landscape, highlighting PPAR agonists and combination OCA and bezafibrate.

A multinational study shows people who achieve sustained virologic response still face a 3-fold greater risk or more of mortality due to liver disease or drug-related issues.

Global estimate prevalence data suggest the virus affects more than 3% of the population, with available treatment and vaccination strategies used too infrequently.

New cross-sectional data show the sex gap in alcohol-related mortality has been narrowing since 1999, as women have become more susceptible to alcohol use and related diseases.

Hepatology experts discuss the use of triple therapy in the management of PBC as the wave of the future.

Experts in hepatology comment on how long they keep a patient with PBC on first-line treatment before deciding to switch to another therapy.

Skyrocketing rates of HCV have aligned with the opioid epidemic—and evidence the need for universal pregnancy screenings.

Though many countries established guidelines and strategies to eliminate the virus by 2030, the region is still behind on newborn virus management.

Hepatology experts review the real-world studies of obeticholic acid for management of PBC, highlighting data that show obeticholic acid could improve clinical outcomes in PBC.

Sonal Kumar, MD, MPH; and Edward Mena, MD, share their approach to managing pruritis brought on by OCA in patients with PBC.

A meta-analysis suggest the correlation between PTH and non-alcoholic fatty liver disease is significant enough for it to be biomarker for disease.

A retrospective analysis shows the highly deadly condition has increased 7-fold among US women in the last 2 decades.

International data show conditions including cirrhosis and alcohol-associated liver disease significantly drive the likelihood of critical illness and death in COVID-19 patients.

An update to guidances prioritizes practices that complete RNA testing on all HCV antibody reactive samples in one step, for the sake of complete test rates.

A Lynchburg-based clinic was able to cure hepatitis C in all follow-through patients with substance abuse who underwent a comprehensive care plan over 8 weeks.

Experts in hepatology discuss safety considerations for use of OCA in patients with cirrhosis and decompensated cirrhosis.

Steven Flamm, MD, FAASLD, FACG, reviews the option of using OCA to manage PBC in patients who cannot tolerate UDCA.

A study from Nepal showed a majority of teaching hospital health providers were accidentally exposed to needles. The group additionally had limited knowledge of their HBV vaccination status.

A meta-analysis shows patients with both NAFLD and type 2 diabetes are at significantly greater risk of hepatic decompensation and HCC over a 5-year span.